Hsiuanlin Wu

S1476 Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension

Bincy Abraham, Randy Longman, Κωνσταντίνος Κατσάνος, Scott D. Lee et autres

us, gr, jp, de, pt (code pays fourni par la source)

S1342 Impact of Baseline Disease Duration on Ozanimod Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 True North Study

Gary R. Lichtenstein, Geert D’Haens, Alissa Walsh, Sarah C. Glover et autres

us, nl, gb (code pays fourni par la source)

S1200 Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study

Raymond Cross, Silvio Danese, Douglas C. Wolf, Katsuyoshi Matsuoka et autres

us, it, jp, il (code pays fourni par la source)

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

Miguel Regueiro, Britta Siegmund, Sara N. Horst, Ryan Moslin et autres

us, de, nl (code pays fourni par la source)

P98 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the true north open-label extension study

Geert D’Haens, Bruce E Sands, Marc Ferrante, Katsuyoshi Matsuoka et autres

nl, us, jp, gb, de, ca (code pays fourni par la source)

Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies

Bruce E. Sands, Geert D’Haens, Remo Panaccione, Miguel Regueiro et autres

us, nl, ca, ie, it (code pays fourni par la source)

Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Corey A. Siegel, David T. Rubin, Millie D. Long, Silvio Danese et autres

Su1791 DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Miguel Regueiro, Geert D’Haens, Raymond K. Cross, Lisa Malter et autres

S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment

Jean‐Frédéric Colombel, Anita Afzali, Douglas C. Wolf, Miguel Regueiro et autres

us, be (code pays fourni par la source)

S901 Group-Based Trajectory Modeling to Identify Response Patterns to Ozanimod Treatment in Patients With Ulcerative Colitis

Parambir S. Dulai, Brian G. Feagan, Bruce E. Sands, Florian Rieder et autres

us, ca, pt, de (code pays fourni par la source)

Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

María T. Abreu, Silvio Danese, Douglas C. Wolf, James B. Canavan et autres

P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study

J F Colombel, David T. Rubin, S Vermeire, A Jain et autres

us, de (code pays fourni par la source)